What is Tissium?
Tissium operates at the intersection of advanced materials science and clinical surgery. The company specializes in the development and manufacturing of synthetic, polymer-based medical devices that facilitate complex procedures such as nerve repair, wound closure, and tissue reinforcement. By leveraging a unique biopolymer platform, Tissium provides surgeons with innovative tools that improve patient outcomes and streamline surgical workflows. Headquartered in Paris, the company has established itself as a critical player in the European medtech landscape, bridging the gap between laboratory-scale innovation and large-scale commercialization of life-saving surgical technologies.
How much funding has Tissium raised?
Tissium has raised a total of $259.5M across 6 funding rounds:
Series A
$27.4M
Series B
$42.8M
Debt
$8.2M
Series C
$59.1M
Series D
$53.8M
Other Financing Round
$68.1M
Series A (2016): $27.5M with participation from Cr�dit Mutuel Innovation, Karista, Sofinnova Partners, and Omnes Venture Capital
Series B (2020): $42.8M led by BNP Paribas Développement, Sofinnova Partners, Bpifrance, Cap Décisif Management, Omnes Capital, European Investment Fund, M&L Investments, CM-CIC Innovation, and ValQuest Partners
Debt (2020): $8.2M supported by Bpifrance, BNP Paribas, and CM-CIC Securities
Series C (2021): $59.1M featuring Cathay Health and Sofinnova Partners
Series D (2023): $53.8M backed by Cathay Capital, Sofinnova Partners, and Mérieux Equity Partners
Other Financing Round (2026): $68.1M with participation from European Investment Bank
Key Investors in Tissium
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. The firm acts as a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage.
Bpifrance
Bpifrance is a French public investment bank that finances companies at every stage of their development through credit, guarantees, and equity, supporting innovation and international expansion.
European Investment Bank
Established in 1958 and headquartered in Luxembourg, the European Investment Bank is the European Union's nonprofit long-term lending and finance institution.
What's next for Tissium?
With the infusion of this latest capital, Tissium is well-positioned to accelerate its international commercialization efforts and deepen its research and development pipeline. The company's strategic roadmap likely involves expanding the clinical applications of its biopolymer technology and scaling manufacturing capabilities to meet global demand. As Tissium transitions into a more mature phase of its lifecycle, the continued support from its diverse investor base—ranging from life sciences-focused venture capital firms to major European financial institutions—will be instrumental in navigating regulatory landscapes and securing market leadership in the competitive surgical device market.
See full Tissium company page
